This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.


  • Research type

    Research Study

  • Full title

    Post-Approval Study Protocol For Hybrid Convergent Of Epicardial RF Ablation And Endocardial Ablation For The Treatment Of Symptomatic Long-standing Persistent AF



  • Contact name

    Jaswinder Gill

  • Contact email

  • Sponsor organisation

    AtriCure, Inc.

  • Identifier


  • Duration of Study in the UK

    4 years, 2 months, 30 days

  • Research summary

    The purpose of the research study is to learn more about the safety and effectiveness of the EPi-Sense®-AF Guided Coagulation System in a large group of subjects with symptomatic long-standing persistent atrial fibrillation (AF). The EPi-Sense®-AF Guided Coagulation System is approved by the FDA for treatment of symptomatic long-standing persistent atrial fibrillation (greater than 12 months duration).
    Up to 325 subjects in the US, UK, and EU will be treated as part of the study. Treated subjects will be assessed for primary safety through 30-days post-procedure and for the primary effectiveness through 12-months post-procedure. Long-term effectiveness information will be obtained through 24- and 36-month assessments.

  • REC name

    London - Harrow Research Ethics Committee

  • REC reference


  • Date of REC Opinion

    10 Feb 2023

  • REC opinion

    Further Information Favourable Opinion

Shape the future of the HRA website.